1. Дедов И.И., Шестакова М.В., Аметов А.С. и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. Сахарный диабет. 2011; 4: 1–17.
2. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemiain type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–79.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.
5. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386–99.
6. Bodmer M, Meier C, Krähenbühl S et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008; 31: 2086–91.
7. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766–77.
8. KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements 2013; 3 (1): 1–150.
9. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011; 12 (1): 57–69.
10. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999; 20: 377–84.
11. Sambol NC, Chiang J, Lin ET et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995; 35: 1094–102.
12. Lalau JD, Vermersch A, Hary L et al. Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 1990; 28: 329–32.
13. Frid A, Sterner GN, Löndahl M et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care 2010; 33: 1291–3.
14. Dell’Aglio DM, Perino LJ, Kazzi Z et al. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med 2009; 54 (6): 818–23.
15. Peters N, Jay N, Barraud D et al. Metformin-associated lactic acidosis in an intensive care unit. Crit Care 2008; 12 (6): R149.
16. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 1: CD002967.
17. Bando K, Ochiai S, Kunimatsu T et al. Comparison of potential risks of lactic acidosis induction by biguanides in rats. Regul Toxicol Pharmacol 2010; 58: 155–60.
18. Stades AM, Heikens JT, Erkelens DW et al. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004; 255: 179–87.
19. Lalau JD, Race JM. Lactic acidosis and metformin therapy: searching for a link with metformin in reports of ‘metformin-associated lactic acidosis’. Diabetes Obes Metab 2001; 3: 195–201.
20. Van Berlo-Van De Laar IR, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011; 36 (3): 376–82.
21. Eurich DT, McAlister FA, Blackburn DF et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335: 497–506.
22. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49 (2) (Suppl. 2): S1-S180.
23. National Institute for Health and Clinical Excellence. The management of type 2 diabetes: clinical guideline CG87 (May 2009): Type 2 diabetes – newer agents (a partial update of CG66). http://www.nice.org.uk/nicemedia/live/12165/ 44320/44320.pdf
24. Canadian Diabetes Association. Clinical practice guidelines 2008. http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf
25. National evidence based guidelines for blood glucose control in type 2 diabetes. http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/di19-diabetes-blood-glucosecontrol.p...
26. Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines and their evidence base on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 2010; 254 (1): 261–9.
27. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34 (6): 1431–7.
28. Klachko D, Whaley-Connell A. Use of metformin in patients with kidney and cardiovascular diseases. Cardiorenal Med 2011; 1 (2): 87–95.
29. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011; 118: c. 380–3.
30. Rocha A, Almedia M, Santos J, Carvalho A. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol 2013; 26 (01): 55–60.

С.В.Виллевальде 

ФГБОУ ВПО Российский университет дружбы народов, Москва